메뉴 건너뛰기
Journal of Drugs in Dermatology
Volumn 7, Issue 12, 2008, Pages 1161-1163
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy
Author keywords

[No Author keywords available]
Indexed keywords

ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;
EID: 60549117569     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (4)
References (12)
  • 1
    • 33748466742 scopus 로고    scopus 로고
    • The PRIDE (papulopustules and or/paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome
    • Lacouture ME, Lai SE. The PRIDE (papulopustules and or/paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol. 2006;155:841-865.
    • (2006) Br J Dermatol , vol.155 , pp. 841-865
    • Lacouture, M.E.1    Lai, S.E.2
  • 2
    • 4043133757 scopus 로고    scopus 로고
    • Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours [5]
    • DOI 10.1111/j.1365-2133.2004.06026.x
    • Bessis D, Jacot W, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151:238-241. (Pubitemid 39061311)
    • (2004) British Journal of Dermatology , vol.151 , Issue.1 , pp. 238-241
    • Jacot, W.1    Bessis, D.2    Jorda, E.3    Ychou, M.4    Fabbro, M.5    Pujol, J.-L.6    Guillot, B.7
  • 4
    • 0036051312 scopus 로고    scopus 로고
    • Follicular and epidermal alterations in patients treated with ZD 1839 (Iressa), an inhibitor of the epidermal growth factor receptor
    • Van Doorn R, Kirtschig G, SchefferE, et al. Follicular and epidermal alterations in patients treated with ZD 1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598-601.
    • (2002) Br J Dermatol , vol.147 , pp. 598-601
    • Van Doorn, R.1    Kirtschig, G.2    Scheffer, E.3
  • 5
    • 33748935930 scopus 로고    scopus 로고
    • Dermatologic side effects associated with the epidermal growth factor inhibitors
    • Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor inhibitors. J Am Acad Dermatol. 2004; 55(4): 657-670.
    • (2004) J Am Acad Dermatol , vol.55 , Issue.4 , pp. 657-670
    • Agero, A.L.1    Dusza, S.W.2    Benvenuto-Andrade, C.3
  • 6
    • 33748942510 scopus 로고    scopus 로고
    • Follikulare arzneimittelreaktion unter einer therapie mit erlotinib (Tarceva)
    • DOI 10.1111/j.1610-0387.2006.06088.x
    • Gerdes S, Mrowietz U. Follicular rash during therapy with erlotinib (Tarceva). Dtsch Dermatol Ges. 2006;4(10):855-857. (Pubitemid 44434329)
    • (2006) JDDG - Journal of the German Society of Dermatology , vol.4 , Issue.10 , pp. 855-857
    • Gerdes, S.1    Mrowietz, U.2
  • 7
    • 34447129570 scopus 로고    scopus 로고
    • Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
    • DOI 10.1158/1078-0432.CCR-06-2610
    • Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913-3921. (Pubitemid 47037599)
    • (2007) Clinical Cancer Research , vol.13 , Issue.13 , pp. 3913-3921
    • Wacker, B.1    Nagrani, T.2    Weinberg, J.3    Witt, K.4    Clark, G.5    Cagnoni, P.J.6
  • 8
    • 33750903340 scopus 로고    scopus 로고
    • Erlotinib-associated skin reactions - Case report and proposal for classification [1]
    • DOI 10.1111/j.1365-2133.2006.07519.x
    • Gross GE, Schad SG, Zoller A. Erlotinib-associated skin reactions-case report and proposal for classification. Br J Dermatol. 2006;155:1293-1295 (Pubitemid 44730011)
    • (2006) British Journal of Dermatology , vol.155 , Issue.6 , pp. 1293-1295
    • Zoller, A.1    Schad, S.G.2    Gross, G.E.3
  • 9
    • 1642303986 scopus 로고    scopus 로고
    • Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor
    • DOI 10.1111/j.1365-2230.2004.01466.x
    • Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of epidermal growth factor receptor. Clin Exp Dermatol. 2004;29:138-140. (Pubitemid 38367194)
    • (2004) Clinical and Experimental Dermatology , vol.29 , Issue.2 , pp. 138-140
    • Fernandez-Galar, M.1    Espana, A.2    Lopez-Picazo, J.M.3
  • 10
    • 26244449709 scopus 로고    scopus 로고
    • Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy [6]
    • DOI 10.1111/j.1365-2133.2005.06835.x
    • Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005;153:849-851. (Pubitemid 41415923)
    • (2005) British Journal of Dermatology , vol.153 , Issue.4 , pp. 849-851
    • Gutzmer, R.1    Werfel, T.2    Mao, R.3    Kapp, A.4    Elsner, J.5
  • 11
    • 0842264243 scopus 로고    scopus 로고
    • Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
    • Lee MW, Seo CW, Kim SW. Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor. Acta Derm Venereol. 2004;84:23-26.
    • (2004) Acta Derm Venereol , vol.84 , pp. 23-26
    • Lee, M.W.1    Seo, C.W.2    Kim, S.W.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.